for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ipsen SA

IPN.PA

Latest Trade

96.20EUR

Change

0.10(+0.10%)

Volume

196,835

Today's Range

94.25

 - 

96.20

52 Week Range

83.80

 - 

128.80

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
96.10
Open
95.85
Volume
196,835
3M AVG Volume
2.84
Today's High
96.20
Today's Low
94.25
52 Week High
128.80
52 Week Low
83.80
Shares Out (MIL)
83.07
Market Cap (MIL)
8,062.96
Forward P/E
14.48
Dividend (Yield %)
1.04

Next Event

Q3 2019 Ipsen SA Corporate Sales Release

Latest Developments

More

Ipsen And Blueprint Medicines Sign Exclusive Global License Agreement For BLU-782

Ipsen Announces FDA Approval Of Dysport® For The Treatment Of Upper Limb Spasticity In Children

Ipsen: Positive Results From Phase IIIb/IV ENGAGE Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ipsen SA

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

Industry

Biotechnology & Drugs

Contact Info

65, quai Georges Gorse

+33.1.58335000

https://www.ipsen.com/

Executive Leadership

Marc de Garidel

Non-Executive Chairman

David Meek

Chief Executive Officer, Director

Antoine Flochel

Vice Chairman of the Board

Aymeric le Chatelier

Chief Financial Officer, Executive Vice President

Regis Mulot

Chief Human Resource Officer, Executive Vice President

Key Stats

2.25 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

1.6K

2017

1.9K

2018

2.2K

2019(E)

2.6K
EPS (EUR)

2016

3.180

2017

4.360

2018

5.910

2019(E)

6.643
Price To Earnings (TTM)
19.76
Price To Sales (TTM)
3.20
Price To Book (MRQ)
4.03
Price To Cash Flow (TTM)
14.50
Total Debt To Equity (MRQ)
56.86
LT Debt To Equity (MRQ)
15.05
Return on Investment (TTM)
15.05
Return on Equity (TTM)
9.98

Latest News

Latest News

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

French pharma group Ipsen closes in on its next drug deals

French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

BRIEF-Ipsen Presents Real-World Pancreatic Cancer Data On ONIVYDE

* REPORTED ON SUNDAY REAL-WORLD PANCREATIC CANCER DATA ON ONIVYDE

BRIEF-Ipsen Q1 Sales up at 510.3 Million Euros

* IPSEN REPORTS STRONG Q1 2018 SALES GROWTH OF 23.1% AT CONSTANT EXCHANGE RATES

BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®

* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

BRIEF-Ipsen Receives Positive CHMP Opinion For Cabometyx

* IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR- RISK ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen Announces Health Canada Approval Of Dysport Therapeutic For Treatment Of Lower Limb Spasticity In Adults

* IPSEN ANNOUNCES HEALTH CANADA APPROVAL OF DYSPORT THERAPEUTIC (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS

French pharma group Ipsen sees more asset purchases, U.S. growth

French pharma company Ipsen expects to bring more drugs to combat cancer, rare diseases and mobility impairment into its pipeline this year and has around one billion euros ($1.25 billion) for asset purchases, its chief executive said.

BRIEF-Ipsen FY IFRS Operating Income Up At 397.2 Million Euros

* IPSEN DELIVERS STRONG 2017 RESULTS WITH 21.1%1 SALES GROWTH AND CORE OPERATING MARGIN INCREASE OF 3.4 POINTS AND EXPECTS SIGNIFICANT FURTHER GROWTH IN SALES AND MARGIN IN 2018

BRIEF-Ipsen Appoints Sotirios G. Stergiopoulos As Chief Medical Officer

* DR SOTIRIOS G. STERGIOPOULOS APPOINTED AS IPSEN CHIEF MEDICAL OFFICER Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients

* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America

* IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

BRIEF-Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​

* ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS

BRIEF-Ipsen ‍reports Q3 2017 group sales growth of 22.6%​

* Q3 GROUP SALES EUR 470.1 MILLION VERSUS EUR 390.6 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ipsen announces success of phase 3 CELESTIAL trial of Cabozantinib

* IPSEN ANNOUNCES THAT PHASE 3 CELESTIAL TRIAL OF CABOZANTINIB MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

BRIEF-Ipsen receives approval from European Commission for Xermelo

* Ipsen receives approval from European Commission for Xermelo® (Telotristat Ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

BRIEF-FDA approves new indication for Ipsen's somatuline depot injection

* U.S. FDA approves new indication for Ipsen's somatuline® depot (lanreotide) injection for the treatment of carcinoid syndrome Source text for Eikon: Further company coverage:

BRIEF-Ipsen annouces US FDA approval of new indication for Somatuline Depot

* U.S. FDA APPROVES NEW INDICATION FOR IPSEN'S SOMATULINE DEPOT (LANREOTIDE) INJECTION FOR THE TREATMENT OF CARCINOID SYNDROME Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up